Alphatec Holdings, Inc.
Alphatec Holdings (NASDAQ:ATEC) reported Q2 2026 revenue of $214 million, up 15% year over year, with surgical revenue at $196 million, up 17%. Adjusted EBITDA rose to $36 million, up 53%, with GAAP gross margin 72.2%. Management reaffirmed full-year revenue guidance near $882 million and raised adjusted EBITDA guidance to about $140 million.
Alphatec Holdings (ATEC) reported Q2 results with a reduced net loss of $25.78 million year over year and reaffirmed 2026 revenue guidance of about $882 million, according to the company. It also filed an $8.12 million shelf registration for 800,000 common shares tied to an ESOP. The update supported a 5.9% stock rise.
Alphatec Holdings (ATEC) reported Q2 2026 revenue of $214 million, up 15% year over year, with surgical revenue at $196 million, up 17%. Adjusted EBITDA rose 53% to $36 million, and GAAP gross margin was 72.2%. Management reaffirmed full-year revenue guidance near $882 million and raised adjusted EBITDA guidance to about $140 million.
Over the past 7 days, alphai's AI scored 3 news stories mentioning ATEC (Alphatec Holdings, Inc.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent ATEC coverage spans earnings, financial news and corporate actions.
In the last 30 days, ATEC insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($79K). The most active reporter was Marshall Tyson Eliot, GENERAL COUNSEL & CORP. SEC., with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
ATEC’s earnings call provides fresh, decision-relevant guidance updates and operating KPIs (cases, surgeons, biologics attachment) that can drive near-term estimate revisions.
Reaffirmed top-line outlook plus smaller losses should support near-term sentiment, while the ESOP shelf adds modest dilution over time risk.
ATEC’s quarter showed strong top-line and EBITDA margin expansion, but revenue per case declined due to stabilized biologics attachment, creating a mixed setup for forward estimates.
Guidance upgrades and margin expansion signals improve near-term earnings power, but revenue-per-case softness and biologics attachment remain key swing factors.
Q2 growth and reaffirmed revenue outlook with higher adjusted EBITDA guidance suggest improving operating leverage and cash generation.
alphai scores every news story that mentions ATEC with an AI model for sentiment and relevance, and aggregates insider trades from Alphatec Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Alphatec Holdings (NASDAQ:ATEC) reported Q2 2026 revenue of $214 million, up 15% year over year, with surgical revenue at $196 million, up 17%. Adjusted EBITDA rose to $36 million, up 53%, with GAAP gross margin 72.2%. Management reaffirmed full-year revenue guidance near $882 million and raised adjusted EBITDA guidance to about $140 million.
6 min readAlphatec Holdings (ATEC) reported Q2 results with a reduced net loss of $25.78 million year over year and reaffirmed 2026 revenue guidance of about $882 million, according to the company. It also filed an $8.12 million shelf registration for 800,000 common shares tied to an ESOP. The update supported a 5.9% stock rise.
4 min readAlphatec Holdings (ATEC) reported Q2 2026 revenue of $214 million, up 15% year over year, with surgical revenue at $196 million, up 17%. Adjusted EBITDA rose 53% to $36 million, and GAAP gross margin was 72.2%. Management reaffirmed full-year revenue guidance near $882 million and raised adjusted EBITDA guidance to about $140 million.
7 min readAlphatec Holdings (ATEC) reported Q2 2026 results driven by 24% growth in new surgeon adoption and 20% procedural volume growth, lifting revenue 15%. Management kept full-year surgical revenue guidance at $805M and raised adjusted EBITDA guidance to $140M. It expects Q3 free cash flow of $4M to $6M and cites margin gains from inventory and supply chain efficiency.
6 min readAlphatec Holdings (Nasdaq: ATEC) reported Q2 2026 revenue of $214 million, up 15% year over year. Surgical revenue was $196 million, up 17%, driven by 20% case volume growth. Adjusted EBITDA was $36 million, 17% of revenue. The company reaffirmed its 2026 outlook: revenue about $882 million and adjusted EBITDA about $140 million.
4 min readAlphatec Holdings, Inc. (ATEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atec-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ATEC Reports Second Quarter Financial Results Total revenue of $214 million, up 15% year-over-year Surgical revenue of $196 million increased 17%, driven by 20% case volume growth Company reaffirms 2026 revenue outlook CARLSB
6 min readStephens initiated coverage of Alphatec Holdings (NASDAQ:ATEC) with an Overweight rating and a $15.00 price target. The firm says Alphatec’s spine surgery strategy focuses on proceduralization and integrated technologies to reduce outcome variability. It cites ATEC’s underperformance, trading at $8.06, and notes mixed Q1 2026 results and analyst target changes.
4 min readAlphatec Holdings, Inc. (ATEC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 atec-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 ALPHATEC HOLDINGS, INC. 2026 EQUITY INCENTIVE PLAN ARTICLE I Purpose The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to
3 min readAlphatec Holdings (ATEC) reported Q1 2026 results on May 5, with total revenue up 14% to $192 million and surgical revenue up 17%. The company posted non-GAAP adjusted EBITDA of $21 million and said a new bank facility would cut annual interest expense by over $6 million and extend maturities to 2031. For 2026, it expects revenue of about $882 million and adjusted EBITDA of about $134 million.
4 min readAlphatec Holdings (ATEC) saw two analyst price-target cuts on May 7 while ratings stayed Overweight. Barclays lowered its target to $24 from $27, citing confidence in long-term growth despite near-term operational issues. Piper Sandler cut its target to $14 from $25 after first-quarter results missed expectations due to a weak EOS quarter and softer revenue per case from product mix headwinds.
3 min read
